Cardiology

Trials, guidelines and practice across cardiovascular medicine.

CardioShift maps hidden heterogeneity in hiPSC-derived cardiomyocytes

CardioShift analyzes single-cell imaging in hiPSC-derived cardiomyocytes, exposing hidden functional heterogeneity and correcting pseudoreplication bias.

By Dr. Aishwarya N., MBBS · Nov 4, 2026 · 5 min read

Cardiology·Med News Today

Tea Intake Linked to Lower Vascular Disease Risk in Large Cohort Study

A large cohort study linked regular tea drinking with lower vascular disease risk, with the strongest association seen…

Nov 4, 2026

Cardiology·Modern HC

Cardiology AI Decision Support Raises Trust and Responsibility Questions

Qualitative interviews found clinicians and patients valued an AI tool for excluding coronary artery disease, while trust, reassurance,…

Nov 4, 2026

Cardiology·JCI

Pulmonary Arterial Hypertension Pathogenesis Points to Reversal Strategies

A JCI review explains how pulmonary arterial hypertension may be reversed by targeting abnormal vascular cell survival and…

Nov 4, 2026

Cardiology·DailyMed

Hydrochlorothiazide label details renal risk, electrolyte monitoring, and glaucoma warning

DailyMed labeling for hydrochlorothiazide reviews renal and electrolyte risks, drug interactions, pregnancy cautions, and rare acute angle-closure glaucoma.

Nov 4, 2026

Cardiology·ScienceDaily

Gene Editing for Heart Disease Raises Safety and Access Questions

A JAMA Internal Medicine perspective weighs gene editing for cholesterol and heart disease against irreversible risk, long-term monitoring,…

Nov 4, 2026

Cardiology·Nature

EASIX Predicts Delirium and Mortality After Valve Surgery

Early postoperative EASIX predicted delirium and in-hospital death after cardiac valve replacement in a MIMIC-IV cohort of 1,543…

Nov 4, 2026

Cardiology·JAMA Onc

Cardiovascular Trial Representation Demands Design-Level Reform

A JAMA Cardiology review outlines policies and trial-design strategies needed to improve representation, validity, and equity in cardiovascular…

Nov 4, 2026

Cardiology·Modern HC

TAVR Cost Pressures Force Hospitals to Rethink Program Economics

Hospitals running TAVR programs face steep costs and tight margins, making efficiency, volume, and care coordination central to…

Nov 4, 2026

Cardiology·JACC

SINGLE-CLOSURE Trial tests one vs two ProGlide devices after TAVR

The SINGLE-CLOSURE Trial examines whether one ProGlide device can secure transfemoral TAVR access as effectively as two devices.

Nov 4, 2026

Cardiology

Trials, guidelines and practice across cardiovascular medicine.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.